The focus will be on R&D related to the relevance of genetic and environmental factors on diseases such as diabetes, carcinogenesis, dementia, myopathy etc. through clinical research. AMED should prioritize long-term fundamental research on prevention, and also on diagnosis and treatment of diseases where genomic medicine can be implemented within 1 – 5 years.

Nikkei Biotech news release, February 15, 2017